Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study

E Cocco; C Sardu; P Gallo; R Capra; Mp Amato; M Trojano; A Uccelli; Mg Marrosu; Anna Paola Batocchi; Group Femims

doi:10.1177/1352458508094882

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study

E Cocco, C Sardu, P Gallo, R Capra, Mp Amato, M Trojano, A Uccelli, Mg Marrosu, Anna Paola Batocchi, Group Femims

Risultato della ricerca: Contributo in rivista › Articolo in rivista

56 Citazioni (Scopus)

Abstract

Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility. FErtility and Mitoxantrone In MS (FEMIMS) is a collaborative retrospective study aimed at evaluating the impact of MITO treatment on fertility in women with MS.

Lingua originale	English
pagine (da-a)	1225-1233
Numero di pagine	9
Rivista	Multiple Sclerosis
Volume	14
DOI	https://doi.org/10.1177/1352458508094882
Stato di pubblicazione	Pubblicato - 2008
Pubblicato esternamente	Sì

Keywords

Immunosuppressive Agents
Infertility, Female
Mitoxantrone
Multiple Sclerosis

Accesso al documento

10.1177/1352458508094882

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{135ac19019c343bba57affd948422e21,

title = "Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study",

abstract = "Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility. FErtility and Mitoxantrone In MS (FEMIMS) is a collaborative retrospective study aimed at evaluating the impact of MITO treatment on fertility in women with MS.",

keywords = "Immunosuppressive Agents, Infertility, Female, Mitoxantrone, Multiple Sclerosis, Immunosuppressive Agents, Infertility, Female, Mitoxantrone, Multiple Sclerosis",

author = "E Cocco and C Sardu and P Gallo and R Capra and Mp Amato and M Trojano and A Uccelli and Mg Marrosu and Batocchi, {Anna Paola} and Group Femims",

year = "2008",

doi = "10.1177/1352458508094882",

language = "English",

volume = "14",

pages = "1225--1233",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "Basingstoke: Stocktom, 1995-. United Kingdom: Arnold",

}

TY - JOUR

T1 - Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study

AU - Cocco, E

AU - Sardu, C

AU - Gallo, P

AU - Capra, R

AU - Amato, Mp

AU - Trojano, M

AU - Uccelli, A

AU - Marrosu, Mg

AU - Batocchi, Anna Paola

AU - Femims, Group

PY - 2008

Y1 - 2008

N2 - Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility. FErtility and Mitoxantrone In MS (FEMIMS) is a collaborative retrospective study aimed at evaluating the impact of MITO treatment on fertility in women with MS.

AB - Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility. FErtility and Mitoxantrone In MS (FEMIMS) is a collaborative retrospective study aimed at evaluating the impact of MITO treatment on fertility in women with MS.

KW - Immunosuppressive Agents

KW - Infertility, Female

KW - Mitoxantrone

KW - Multiple Sclerosis

KW - Immunosuppressive Agents

KW - Infertility, Female

KW - Mitoxantrone

KW - Multiple Sclerosis

UR - http://hdl.handle.net/10807/20712

U2 - 10.1177/1352458508094882

DO - 10.1177/1352458508094882

M3 - Article

SN - 1352-4585

VL - 14

SP - 1225

EP - 1233

JO - Multiple Sclerosis

JF - Multiple Sclerosis

ER -

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo